|
Match
|
Document |
Document Title |
|
|
7517951 |
Marker proteins for diagnosing liver disease and method of diagnosing liver disease using the same
Using the protein chip technology, biological samples such as sera are subjected to proteome analysis. Thus, a protein which is a human fibrinogen α-E chain decomposition product and has a...
|
|
|
7442308 |
Process for removing viruses in fibrinogen solutions and fibrinogen obtained by said process
A process for removing viruses in fibrinogen solutions and fibrinogen obtained thereof wherein the process starts with an adjusted purified fibrinogen solution, the adjusted purified solution is...
|
|
|
7351422 |
Hemostatic soluble cellulose fibers containing coagulating protein for treating wound and process for producing the same
Proposed is a novel soluble trauma-healing and hemostatic cellulose fiber capable of absorbing and readily dissolving hemorrhaging trauma loci when applied thereto and of promoting the hemostatic...
|
|
|
7348411 |
Process for manufacturing fibrin membranes and fibrin membranes obtained according to this process
A process for manufacturing a fibrin membrane from blood plasma that was partially depleted and subjected to coagulation by adding a solution of a physiological coagulating agent, leaving the...
|
|
|
7323442 |
Agents for alleviating symptoms accompanied by inflammation
The present invention provides agents for alleviating symptoms resulting from inflammation, which have an activity to alleviate inflammatory symptoms caused by bacterial infection, particularly...
|
|
|
7220836 |
Dried blood factor composition comprising trehalose
A stable blood factor composition contains a stabilising amount of trehalose in the absence of human serum albumin to provide a product stable at up to 60° C.
|
|
|
7211650 |
Purification of fibrinogen from fluids by precipitation and hydrophoic chromatography
The present invention provides a method for the part purification of fibrinogen from milk, the method comprising the transfer of protease enzyme which is present in the milk, into the whey phase...
|
|
|
7211651 |
Proteinaceous gels having visualization agents and methods of use thereof
Proteinaceous gels having visualization agents and methods of use thereof are disclosed herein. Further, polymeric crosslinking agents are disclosed that have an inert water soluble polymeric...
|
|
|
7153830 |
Method for inhibiting the formation of seromas using factor XIII
Use of factor XIII for inhibiting the formation of seromas by administering factor XIII. The factor XIII can be administered locally at the site of a wound or surgery or administered systemically....
|
|
|
7148190 |
Haptotactic peprides
We disclose haptotactic peptides having sequences homologous to specific portions of the carboxy terminal sequence of fibrinogen chains. The peptides derived from fibrinogen pre-Cγ chain possess...
|
|
|
RE39321 |
Supplemented and unsupplemented tissue sealants, methods of their production and use
This invention provides a fibrin sealant dressing, wherein said fibrin sealant may be supplemented with at least one composition selected from, for example, one or more regulatory compounds,...
|
|
|
7087722 |
Fibrin binding domain polypeptides and uses and methods of producing same
This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding...
|
|
|
RE39192 |
Supplemented and unsupplemented tissue sealants, methods of their production and use
This invention provides supplemented tissue sealants, methods for their production and use thereof. Disclosed are tissue sealants supplemented with at least one cytotoxin or cell proliferation...
|
|
|
7045601 |
Storage-stable, liquid fibrinogen formulation
The present invention relates to a novel storage-stable formulation for fibrinogen in liquid or viscous liquid form comprising divalent metal ions. The fibrinogen formulation may comprise other...
|
|
|
7008800 |
Biopolymer marker indicative of disease state having a molecular weight of 1077 daltons
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers...
|
|
|
7009034 |
Biocompatible crosslinked polymers
Biocompatible crosslinked polymers, and methods for their preparation and use, are disclosed in which the biocompatible crosslinked polymers are formed from water soluble precursors having...
|
|
|
7001989 |
Conjugates comprising two active agents
The present invention pertains to a pharmaceutical conjugate comprising an insoluble carrier to which first and second active agents are bound, respectively via a first linker to a first functional...
|
|
|
6965014 |
Fibrin material and method for producing and using the same
This invention describes a bioerodible fibrin material which is obtained by mixing fibrinogen and thrombin reconstituted or diluted with a particular high tonic strength medium, free of calcium....
|
|
|
6960463 |
Separation of fibrinogen from plasma proteases
The present invention relates to methods for purifying fibrinogen. In one aspect, the present invention relates to a method of separating fibrinogen from plasma fraction I precipitate. In another...
|
|
|
6916911 |
Use of fibrinogen multimers
Use of fibrinogen multimers having at least 6 fibrinogen units as an ingredient for a fibrin sealant.
|
|
|
6887974 |
Crosslinking agents and methods of use
Polymeric crosslinking agents are disclosed that have an inert water soluble polymeric component, biodegradable components, functional components reactive with chemical groups on a protein, for...
|
|
|
6869790 |
Preparation of DNA encoding factor XIIIA
The cDNA which codes for factor XIIIa has been isolated using a cDNA bank from human placenta and probes constructed on the basis of the amino acid sequence of factor XIIIa peptide fragments. It is...
|
|
|
6867285 |
Virus-free plasma protein compositions treated with porous membrane and process for producing the same
Contaminant viruses can be efficiently removed almost without losing the activity of protein by subjecting a plasma protein composition having a high risk of viral contamination to a treatment with...
|
|
|
6835378 |
Method and compositions for inhibiting thrombin-induced coagulation
A method of achieving safe and effective treatment or prevention of potentially harmful blood clots, or in inhibiting the coagulation of blood when so desired such as during a wide array of disease...
|
|
|
6780411 |
Tissue sealant compositions
Tissue sealant compositions containing human recombinant fibrinogen, human recombinant factor XIII and human recombinant thrombin. Also disclosed are preferred formulations and uses therefore.
|
|
|
6759042 |
Use of cross-linked, covalently bound urokinase plasminogen activator (scuPA)-urokinase plasminogen activator receptor (suPAR) complex as a fibrinolytic agent
The present invention relates to the cross-linked scuPA/suPAR complex and/or tcuPA/suPAR cross-linked complex, the process of preparation of the covalently bound single compound having fibrinolytic...
|
|
|
6740736 |
Purification of fibrinogen from milk by use of cation exchange chromatography
Fibrinogen is obtained from milk by contact with a cation exchange chromatography substrate under conditions where the fibrinogen binds to the substrate, followed by optional washing of the...
|
|
|
6737074 |
Methods of separating cells, transplanting cells and engineering tissue using fibrin microbeads
The present invention provides fibrin microbeads that are biologically active and comprise extensively cross-linked fibrin(ogen), and a method for preparing the fibrin microbeads. The present...
|
|
|
6696276 |
Vasopermeability-enhancing conjugates
Liposomal conjugates having a clinically useful delivery vehicle linked to a biologically active species which acts to increase vascular permeability and expand blood volume at or in proximity to...
|
|
|
6693173 |
Method to remove citrate and aluminum from proteins
A method is provided for removing citrate, aluminum, and other multivalent ions and contaminants from proteins by adjusting the pH of a solution containing the protein to a pH from about 7 to about...
|
|
|
6660842 |
Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
The present invention generally relates to compositions and methods for preventing and treating human diseases including, but not limited to, pathogens such as bacteria, yeast, parasites, fungus,...
|
|
|
6632648 |
Methods of terminal sterilization of fibrinogen
The invention relates to methods of sterilizing biologically active products, particularly therapeutic or prophylactic products and the compositions obtained thereby. The methods include obtaining...
|
|
|
6610538 |
Reconstructed laminae of human epithelium corneae and method of producing the same
A method of reconstructing laminae of human epithelium corneae in vitro to be used in grafts from cultures of limbar stem cells as well as a method of selecting and transferring such cells to...
|
|
|
6558687 |
Fibrin polymer structure
In accordance with the present invention a novel fibrin polymer structure is disclosed. The novel fibrin polymer structure useful, for example, as a surgical sealant, is comprised of a plurality of...
|
|
|
6552172 |
Fibrin nanoparticles and uses thereof
The present invention provides fibrin nanoparticles having a mean diameter of 200-2000 nm. The present invention provides also methods for preparing fibrin particles of various sizes, including...
|
|
|
6551794 |
Stable biotinylated biomolecule composition
Stable compositions containing biotinylated molecules, such as enzymes, are provided. The compositions include a biotinylated biomolecule, a biomolecule protectant, a buffer, a bulking agent...
|
|
|
6531577 |
von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
A high-purity von Willebrand factor preparation, a process for making it, and use of the preparation and compositions containing it for the treatment of disorders are disclosed.
|
|
|
6503731 |
Fibrin microbeads prepared from fibrinogen, thrombin and factor XIII for binding cells
Fibrin microbeads are prepared containing extensively cross-linked fibrin (ogen) without using glutaraldehyde. The fibrin microbeads are preferably prepared by containing an aqueous solution...
|
|
|
6500924 |
Methods and compositions useful for inhibition of angiogenesis
The present invention describes methods for inhibition of angiogenesis in tissues using vitronectin α v β 3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in...
|
|
|
6492494 |
Method of making a fibrin sealant comprising alpha-2-antiplasmin
The invention provides a kit for preparing a fibrin sealant either (A) comprising: (a) a fibrin monomer preparation; (b) a stabilizing preparation containing a clot-preserving effective amount of a...
|
|
|
6462021 |
Use of low molecular weight thrombin inhibitor
According to the invention there is provided the use of melagatran, or a pharmaceutically-acceptable derivative thereof, for the manufacture of a medicament for the treatment of ischemic disorders...
|
|
|
6447774 |
Stabilized protein preparations for a tissue adhesive
A tissue adhesive is described, which contains three separate components, i.e., a stabilized, essentially fibrinogen-free protein preparation that is of storage-quality in liquid state and...
|
|
|
6416717 |
Evacuated blood collection tube for rapid blood coagulation
Providing an evacuated blood collection tube for blood collection rapidly, whereby serum of high purity can be isolated in a rapid and simple manner with no occurrence of fibrin deposition. Beads...
|
|
|
6319498 |
Modulators of amyloid aggregation
Compounds that modulate the aggregation of amyloidogenic proteins or peptides are disclosed. The modulators of the invention can promote amyloid aggregation or, more preferably, can inhibit natural...
|
|
|
6280727 |
Compositions containing thrombin and microfibrillar collagen and methods for preparation and use thereof
The present invention relates to thrombin-containing hemostatic compositions, their preparation and use. In particular, it relates to hemostatic compositions comprising stabilized thrombin and...
|
|
|
6277961 |
Stable fibrinogen solution
A fibrinogen solution which is suitable for use in a tissue adhesive and can be stored at temperatures between +4° C. and +25° C. for at least four weeks without loss of its ability to function,...
|
|
|
6274343 |
Vasopermeability enhancing immunoconjugates
Conjugates having a clinically useful delivery vehicle linked to a biologically active species which acts to increase vascular permeability and expand blood volume at or in proximity to the tumor...
|
|
|
6268483 |
Compositions useful as fibrin sealants
Novel fibrin monomer compositions which are solutions including additional coharvested components, such as prothrombin and Factor XIII, are useful in fibrin sealant applications. Preferably, the...
|
|
|
6268344 |
Methods for treating hypercoagulable states or acquired protein C deficiency
A method of treatment for human patients with an acquired hypercoagulable state or acquired protein C deficiency associated with sepsis, purpura fulminans, meningococcal sepsis, bone marrow and...
|
|
|
6264988 |
Fibrinogen-coated microspheres
The invention provides compositions comprising microspheres of fibrinogen-coated cross-linked albumin microspheres having a size range of primarily from about 100 to about 5000 nanometers diameter,...
|